Global Anthrax Vaccines Revenue Is Nearly 470 Million USD In 2016
Tuesday, 06 Nov, 2018
In the last several years, global market of Anthrax Vaccines developed rapidly, with an average growth rate of 7.6 %. In 2016, global revenue of Anthrax Vaccines is nearly 470 million USD; the actual production is about 540 million Doses.

Along with the development of China 's Agricultural technology, there is a lot Chinese local manufacturer can produce Anthrax Vaccines, with the increasing demand, more and more manufactures will go into Anthrax Vaccines industry.

The classification of Anthrax Vaccines includes Live?Vaccines and Cell?free?PA?Vaccines, and the revenue proportion of Live?Vaccines in 2016 is about 43%.

Anthrax Vaccines are widely used for human and animal. The most proportion of Anthrax Vaccines is used for animal, and the consumption proportion is about 95.1% in 2016.

South America region is the largest supplier of Anthrax Vaccines, with a production market share nearly 34.7% in 2016. Europe is the second largest supplier of Anthrax Vaccines, enjoying production market share nearly 17.6% in 2016.

South America is the largest sales place, with a sales market share nearly 39.3% in 2016. Following South America, Europe is the second largest sales place with the sales market share of 19.1%. 

Market competition is intense. Emergent BioSolutions is the major manufacturer of Anthrax Vaccines used for human, Merial, Merck, Zoetis, Bayer Sanidad Animal,Colorado Serum, etc. are is the major manufacturer of Anthrax Vaccines used for animal, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.